{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:19:37Z","timestamp":1787581177049,"version":"build-2736575974"},"reference-count":72,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Metastatic colorectal cancer (mCRC) remains one of the leading causes of cancer deaths worldwide. Mutations of the RAS and BRAF genes and the location of the primary tumor determine the choice of systemic therapy. Panitumumab\u2014a fully human anti-EGFR monoclonal antibody\u2014is well-established in the treatment of patients with wild-type RAS and BRAF and left-sided tumor localization. The aim of this review is to summarize the role and potential of targeted therapies for colorectal cancer with monoclonal antibodies such as panitumumab or cetuximab, to provide current evidence on the position of panitumumab in the treatment of mCRC, and to discuss biomarkers and qualification strategies for targeted therapy, including the role of ctDNA in disease monitoring and rechallenge. The work is based on a narrative review of literature from the PubMed, Scopus, Web of Science and Google Scholar databases, including publications available until May 2026. The efficacy of panitumumab was confirmed in phase III studies: first-line (PRIME: prolongation of OS by 5.6 months) and second-line treatment. A key condition for eligibility is complete RAS and BRAF genotyping, assessment of MSI\/dMMR status, HER2 amplification, and tumor location. ctDNA analysis enables monitoring of tumor clonal evolution and qualification for rechallenge\u2014the CHRONOS study showed 30% objective responses with liquid biopsy-based selection. Associations with BRAF\/MEK and KRAS G12C inhibitors and modulation of the immune microenvironment via the CCL5\/CCR5 axis remain promising directions. Panitumumab occupies an important position in the treatment of patients with mCRC, but increasingly precise molecular stratification and dynamic monitoring of disease with ctDNA are becoming the basis for the effective and rational use of the drug. Unlike reviews that selectively focus on individual aspects of anti-EGFR therapy, the following work integrates all aspects: from molecular biology and biomarkers used to qualify patients to clinical data on panitumumab and new strategies in the fight against mCRC. Further development of next-generation sequencing methods and standardization of ctDNA panels will be crucial for the widespread deployment of targeted therapies in everyday clinical practice. The role of panitumumab is well established in appropriately selected patients with RAS wild-type, particularly left-sided, metastatic colorectal cancer (mCRC). Combining panitumumab with immune checkpoint inhibitors warrants further investigation, particularly in patients with MSS\/pMMR mCRC. The observed activity of panitumumab in combination with nivolumab and ipilimumab provides a rationale for further clinical evaluation and monitoring.<\/jats:p>","DOI":"10.3390\/ijms27177559","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:20:43Z","timestamp":1787577643000},"page":"7559","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Monoclonal Antibody Targeted Therapy (Panitumumab) in the Treatment of Metastatic Colorectal Cancer\u2014A Narrative Review of Current Evidence and Emerging Therapeutic Strategies"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5271-0153","authenticated-orcid":false,"given":"Lidia","family":"Kwiatkowska","sequence":"first","affiliation":[{"name":"Department of Bromatology and Nutritional Diagnostics, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9808-0624","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Szczuko","sequence":"additional","affiliation":[{"name":"Department of Bromatology and Nutritional Diagnostics, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1186\/s12967-025-06876-7","article-title":"Factors Affecting Survival in Patients with Colorectal Cancer: An Umbrella Review","volume":"23","author":"Yu","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1101\/gad.348226.120","article-title":"Genetic and Biological Hallmarks of Colorectal Cancer","volume":"35","author":"Li","year":"2021","journal-title":"Genes Dev."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Paduraru, D.N., Palcau, A.C., Dinca, V.G., Ciuc, D.M., and Constantinescu, A. (2025). The Role of Gut Microbiota in Colorectal Cancer Pathogenesis: A Comprehensive Literature Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262411870"},{"key":"ref_4","unstructured":"WHO (2026, July 01). Cancer Colorecal. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/colorectal-cancer."},{"key":"ref_5","unstructured":"Kufe, D.W., Pollock, R.E., and Weichselbaum, R.R. (2026, May 09). Stage IV Colorectal Cancer, Holland-Frei Cancer Medicine, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK13267\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.14740\/gr1167","article-title":"A Systematic Literature Review and Meta-Analysis Describing the Prevalence of KRAS, NRAS, and BRAF Gene Mutations in Metastatic Colorectal Cancer","volume":"13","author":"Bylsma","year":"2020","journal-title":"Gastroenterol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Li\u0219cu, H.-D., Verga, N., Atasiei, D.-I., Badiu, D.-C., Dumitru, A.V., Ultimescu, F., Pavel, C., Stefan, R.-E., Manole, D.-C., and Ionescu, A.-I. (2024). Biomarkers in Colorectal Cancer: Actual and Future Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252111535"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic Colorectal Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cac2.12639","article-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Colorectal Cancer, 2024 Update","volume":"45","author":"Wang","year":"2025","journal-title":"Cancer Commun."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Santiago, L., Huntley Pascual, D., S\u00e1nchez Lara, J.S., Huerta, M., and Dorcaratto, D. (2026). How to Integrate Surgery into the Multidisciplinary Treatment of Liver-Only Metastatic Colorectal Cancer. Cancers, 18.","DOI":"10.3390\/cancers18030489"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lindner, D.J., Drazba, J.A., Parker, Y.A., Guinta, K., Graham, A., Parsons-Wingerter, P.A., Pancsa, R., Pestell, R.G., and Burger, D.R. (2025). Leronlimab Inhibits Colon Carcinoma Metastasis in a Humanized Mouse Xenograft Model. Immunol. Microbiol., Preprint.","DOI":"10.20944\/preprints202511.0394.v1"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Chen, J., Zhao, J., Zhang, X., and Zhu, H. (2026). Gut Microbiota Regulation and Traditional Chinese Medicine Syndrome Differentiation in Right- and Left-Sided Colon Cancer Heterogeneity\u2014A Review. Front. Pharmacol., 17.","DOI":"10.3389\/fphar.2026.1768252"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41431-025-01913-x","article-title":"EMQN Best Practice Guidelines for Analysis and Reporting of Microsatellite Instability in Solid Tumours","volume":"34","author":"Gallon","year":"2026","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lin, A., Zhang, J., and Luo, P. (2020). Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.02039"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.5306\/wjco.v15.i4.540","article-title":"Comparative Effectiveness of Immunotherapy and Chemotherapy in Patients with Metastatic Colorectal Cancer Stratified by Microsatellite Instability Status","volume":"15","author":"Niu","year":"2024","journal-title":"World J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-024-02063-2","article-title":"Clinical Application of Liquid Biopsy in Colorectal Cancer: Detection, Prediction, and Treatment Monitoring","volume":"23","author":"Tao","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41416-022-01769-8","article-title":"Liquid Biopsies to Monitor and Direct Cancer Treatment in Colorectal Cancer","volume":"127","author":"Mauri","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hench, I.B., Hench, J., and Tolnay, M. (2018). Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer. Front. Med., 5.","DOI":"10.3389\/fmed.2018.00009"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ziranu, P., Pretta, A., Saba, G., Spanu, D., Donisi, C., Ferrari, P.A., Cau, F., D\u2019Agata, A.P., Piras, M., and Mariani, S. (2025). Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions. Int. J. Mol. Sci., 26, Correction in Int. J. Mol. Sci. 2026, 27, 2535. https:\/\/doi.org\/10.3390\/ijms27062535.","DOI":"10.3390\/ijms27062535"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12957-018-1544-x","article-title":"Clinicopathological and Prognostic Significance of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis","volume":"17","author":"Shen","year":"2019","journal-title":"World J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40265-025-02253-2","article-title":"Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies","volume":"86","author":"Vaghi","year":"2026","journal-title":"Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41467-025-67824-z","article-title":"Tucatinib plus Trastuzumab for Chemotherapy-Refractory, HER2 +, RAS Wild-Type Metastatic Colorectal Cancer (MOUNTAINEER): Final Analysis","volume":"17","author":"Strickler","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1158\/1078-0432.CCR-23-1041","article-title":"FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2 -Positive RAS Wild-Type Colorectal Cancer","volume":"29","author":"Casak","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00280-014-2401-4","article-title":"Overexpression of MET Is a New Predictive Marker for Anti-EGFR Therapy in Metastatic Colorectal Cancer with Wild-Type KRAS","volume":"73","author":"Kishiki","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"54627","DOI":"10.18632\/oncotarget.10559","article-title":"MET Amplification in Metastatic Colorectal Cancer: An Acquired Response to EGFR Inhibition, Not a de Novo Phenomenon","volume":"7","author":"Raghav","year":"2016","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2159-8290.CD-12-0558","article-title":"Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer","volume":"3","author":"Bardelli","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"18056","DOI":"10.3390\/ijms140918056","article-title":"Role of cMET in the Development and Progression of Colorectal Cancer","volume":"14","author":"Biondani","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1038\/s41598-021-85075-y","article-title":"NTRK Fusion in Japanese Colorectal Adenocarcinomas","volume":"11","author":"Yamashiro","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e008722","DOI":"10.1136\/jitc-2023-008722","article-title":"CCR5 and CCL5 in Metastatic Colorectal Cancer","volume":"12","author":"Schlechter","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e007939","DOI":"10.1136\/jitc-2023-007939","article-title":"CCR5 and CCL5 Gene Expression in Colorectal Cancer: Comprehensive Profiling and Clinical Value","volume":"12","author":"Battaglin","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12032-015-0607-x","article-title":"CCR5 Blockage by Maraviroc Induces Cytotoxic and Apoptotic Effects in Colorectal Cancer Cells","volume":"32","author":"Pervaiz","year":"2015","journal-title":"Med. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2022.03.017","article-title":"Pembrolizumab and Maraviroc in Refractory Mismatch Repair Proficient\/Microsatellite-Stable Metastatic Colorectal Cancer\u2014The PICCASSO Phase I Trial","volume":"167","author":"Haag","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","article-title":"Circulating Tumor DNA to Guide Rechallenge with Panitumumab in Metastatic Colorectal Cancer: The Phase 2 CHRONOS Trial","volume":"28","author":"Pietrantonio","year":"2022","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1158\/1078-0432.CCR-19-0823","article-title":"Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies","volume":"25","author":"Parseghian","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1158\/1078-0432.CCR-16-1863","article-title":"Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer","volume":"23","author":"Pietrantonio","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3747\/co.v17is1.616","article-title":"Efficacy of the Monoclonal Antibody EGFR Inhibitors for the Treatment of Metastatic Colorectal Cancer","volume":"17","author":"Fakih","year":"2010","journal-title":"Curr. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.18632\/oncotarget.14012","article-title":"Mechanisms of Resistance to Anti-EGFR Therapy in Colorectal Cancer","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/1078-0432.CCR-07-0065","article-title":"Panitumumab, a Monoclonal Anti\u2013Epidermal Growth Factor Receptor Antibody in Colorectal Cancer: Another One or the One?","volume":"13","author":"Messersmith","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Foncillas, J., Sunakawa, Y., Aderka, D., Wainberg, Z., Ronga, P., Witzler, P., and Stintzing, S. (2019). Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00849"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","article-title":"Panitumumab versus Cetuximab in Patients with Chemotherapy-Refractory Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer (ASPECCT): A Randomised, Multicentre, Open-Label, Non-Inferiority Phase 3 Study","volume":"15","author":"Price","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., and Shamseddine, A. (2026). EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27073265"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer","volume":"25","author":"Peeters","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","article-title":"Final Results from PRIME: Randomized Phase III Study of Panitumumab with FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer","volume":"25","author":"Douillard","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs Bevacizumab Added to Standard First-Line Chemotherapy and Overall Survival Among Patients with RAS Wild-Type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/annonc\/mdt523","article-title":"Final Results from a Randomized Phase 3 Study of FOLFIRI \u00b1 Panitumumab for Second-Line Treatment of Metastatic Colorectal Cancer","volume":"25","author":"Peeters","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejca.2017.04.024","article-title":"First-Line Panitumumab plus FOLFOX4 or FOLFIRI in Colorectal Cancer with Multiple or Unresectable Liver Metastases: A Randomised, Phase II Trial (PLANET-TTD)","volume":"81","author":"Carrato","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1002\/cncr.28223","article-title":"Panitumumab in Combination with Infusional Oxaliplatin and Oral Capecitabine for Conversion Therapy in Patients with Colon Cancer and Advanced Liver Metastases: The MetaPan Study","volume":"119","author":"Leone","year":"2013","journal-title":"Cancer"},{"key":"ref_49","first-page":"170","article-title":"Effect of Primary Tumor Location on Second- or Later-Line Treatment Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer and All Treatment Lines in Patients with RAS Mutations in Four Randomized Panitumumab Studies","volume":"17","author":"Boeckx","year":"2018","journal-title":"Clin. Color. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO-25-01337","article-title":"Upfront Modified FOLFOXIRI Plus Panitumumab for RAS\/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study","volume":"44","author":"Conca","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin Toxicity Evaluation Protocol with Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients with Metastatic Colorectal Cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_52","unstructured":"(2026, August 16). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vectibix."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","article-title":"Encorafenib, Cetuximab and Chemotherapy in BRAF-Mutant Colorectal Cancer: A Randomized Phase 3 Trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Chitoran, E., Rotaru, V., Stefan, D.-C., Gullo, G., and Simion, L. (2025). Blocking Tumoral Angiogenesis VEGF\/VEGFR Pathway: Bevacizumab\u201420 Years of Therapeutic Success and Controversy. Cancers, 17.","DOI":"10.3390\/cancers17071126"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/GICTT.S97740","article-title":"Spotlight on Bevacizumab in Metastatic Colorectal Cancer: Patient Selection and Perspectives","volume":"6","author":"Bupathi","year":"2016","journal-title":"Gastrointest. Cancer Targets Ther."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Huo, L., Yue, H., Yang, R., Sun, X., Wang, Z., Liu, H., Liu, J., Feng, R., and Liang, P. (2025). Efficacy and Safety of First-Line Targeted and Immunotherapy for Metastatic Colorectal Cancer: A Network Meta-Analysis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1643133"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E\u2013Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","article-title":"Sotorasib with Panitumumab in Chemotherapy-Refractory KRASG12C-Mutated Colorectal Cancer: A Phase 1b Trial","volume":"30","author":"Kuboki","year":"2024","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"102746","DOI":"10.1016\/j.clinre.2025.102746","article-title":"Switch from Cetuximab to Panitumumab during Encorafenib-Based Therapy in BRAF V600E Mutated Metastatic Colorectal Cancer: An International Multicenter Analysis from the AGEO Group","volume":"50","author":"Gandini","year":"2026","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/OTT.S500281","article-title":"Progress of Immune Checkpoint Inhibitors Therapy for pMMR\/MSS Metastatic Colorectal Cancer","volume":"17","author":"Qu","year":"2024","journal-title":"OncoTargets Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s11912-024-01583-w","article-title":"Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can We Close the Gap between Potential and Practice?","volume":"26","author":"Hamid","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e2400086","DOI":"10.1200\/OA-24-00086","article-title":"Phase II Study of Ipilimumab, Nivolumab, and Panitumumab in Patients with KRAS\/NRAS\/BRAF Wild-Type Microsatellite Stable Metastatic Colorectal Cancer","volume":"2","author":"Somasundaram","year":"2025","journal-title":"JCO Oncol. Adv."},{"key":"ref_66","unstructured":"UNC Lineberger Comprehensive Cancer Center (2026, July 01). Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS\/NRAS\/BRAF Wild-Type MSS Refractory Metastatic Colorectal Adenocarcinoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03442569."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Mansur, A., Saleem, Z., Elhakim, T., and Daye, D. (2023). Role of Artificial Intelligence in Risk Prediction, Prognostication, and Therapy Response Assessment in Colorectal Cancer: Current State and Future Directions. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1065402"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1038\/s41388-025-03582-y","article-title":"Adaptive Cancer Therapy: Can Non-Genetic Factors Become Its Achilles Heel?","volume":"44","author":"Valcz","year":"2025","journal-title":"Oncogene"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.24.00979","article-title":"Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial","volume":"43","author":"Avallone","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO Recommendations on the Use of Circulating Tumour DNA Assays for Patients with Cancer: A Report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10732748261458456","DOI":"10.1177\/10732748261458456","article-title":"New Compass for Precision Oncology: Evidence, Challenges, and Prospects of Circulating Tumor DNA in Colorectal Cancer","volume":"33","author":"Suzuki","year":"2026","journal-title":"Cancer Control"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Kasi, P.M., Baron, A., Chaudhry, A., Tenner, L., Adams, D.L., Duffy, A.B., Rui, H., Vittner, P., Meidling, J., and Lalezari, J.P. (2026). Abstract 6466: Preliminary Results of a Phase 2 Study of Leronlimab in Combination with TAS-102 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer. Cancer Res., 86.","DOI":"10.1158\/1538-7445.AM2026-6466"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7559\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:21:23Z","timestamp":1787577683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":72,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177559"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177559","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}